PHILADELPHIA - The American Society of Consultant Pharmacists will form an independent, interdisciplinary panel with the Alliance for Aging Research to examine medication-related problems in nursing facilities, the association announced at its annual meeting in November.
PHILADELPHIA - The American Society of Consultant Pharmacists will form an independent, interdisciplinary panel with the Alliance for Aging Research to examine medication-related problems in nursing facilities, the association announced at its annual meeting in November.
The panel will prepare a report recommending public policy actions for Congress. The ASCP hopes that policy-makers will strengthen the role of consultant pharmacists as medication experts for the elderly, according to R. Tim Webster, executive director of the ASCP.
According to a study supported by the ASCP's Research and Education Foundation, published in the Oct. 13 issue of Archives of Internal Medicine, the United States saves $3.6 billion annually on medication-related problems, and improves patient outcomes by 43% through pharmacist-conducted drug-regimen reviews in nursing facilities. The study estimated that preventable medication-related problems in nursing homes could cost as much as $7.6 million per year without the intervention of consultant pharmacists. PR
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.